White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers

L.J.C. Van Waalwijk Van Doorn, M. Ghafoorian, E.M.C. Van Leijsen, J.A.H.R. Claassen, A. Arighi, M. Bozzali, J. Cannas, E. Cavedo, P. Eusebi, L. Farotti, C. Fenoglio, J. Fortea, G.B. Frisoni, D. Galimberti, V. Greco, S.-K. Herukka, Y. Liu, A. Lleó, A. De Mendonça, F.M. NobiliL. Parnetti, A. Picco, M. Pikkarainen, N. Salvadori, E. Scarpini, H. Soininen, R. Tarducci, A. Urbani, E. Vilaplana, O. Meulenbroek, B. Platel, M.M. Verbeek, H.B. Kuiperij, R. Martins

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)163-175
Number of pages13
JournalJournal of Alzheimer's Disease
Volume79
Issue number1
DOIs
Publication statusPublished - 2021

Keywords

  • Alzheimer's disease
  • amyloid
  • biomarkers
  • cerebrospinal fluid
  • magnetic resonance imaging
  • tau proteins
  • white matter hyperintensities
  • white matter lesions
  • amyloid beta protein[1-42]
  • biological marker
  • cell protein
  • phosphoprotein
  • tau protein
  • adult
  • Alzheimer disease
  • Article
  • automation
  • brain size
  • brain ventricle
  • comparative study
  • computer aided design
  • computer assisted diagnosis
  • controlled study
  • data analysis software
  • demography
  • detection algorithm
  • enzyme linked immunosorbent assay
  • female
  • human
  • image processing
  • image segmentation
  • lumbar puncture
  • machine learning
  • major clinical study
  • male
  • memory disorder
  • middle aged
  • mild cognitive impairment
  • neuroimaging
  • nuclear magnetic resonance imaging
  • prevalence
  • priority journal
  • protein cerebrospinal fluid level
  • standardization
  • white matter lesion

Cite this